Reviewing NanoViricides (NYSE:NNVC) & Spruce Biosciences (NASDAQ:SPRB)

Spruce Biosciences (NASDAQ:SPRB) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Spruce Biosciences and NanoViricides, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	3	4	0	2.38
NanoViricides	0	0	1	0	3.00

Spruce Biosciences currently has a consensus price target of $170.10, suggesting a potential upside of 169.83%. Given Spruce Biosciences’ higher possible upside, research analysts plainly believe Spruce Biosciences is more favorable than NanoViricides.

Earnings and Valuation

This table compares Spruce Biosciences and NanoViricides”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91 million	17.59	-$38.97 million	($51.72)	-1.22
NanoViricides	N/A	N/A	-$8.29 million	($0.48)	-1.89

NanoViricides has lower revenue, but higher earnings than Spruce Biosciences. NanoViricides is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spruce Biosciences and NanoViricides’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-203.99%	-127.96%
NanoViricides	N/A	-87.90%	-78.69%

Volatility and Risk

Spruce Biosciences has a beta of 3.62, indicating that its share price is 262% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Insider & Institutional Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by insiders. Comparatively, 3.6% of NanoViricides shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats NanoViricides on 7 of the 12 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About NanoViricides

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.